Researcher.Life Logo

Cell Reports Medicine : Impact Factor & More

eISSN: 2666-3791pISSN: 2666-3791
JournalOpen Access

Key Metrics

CiteScore
7.1
Impact Factor
10 - 15
Scite Index
0.90 5-Year SI
SJR
Q3Biochemistry, Genetics and Molecular Biology (all)
SNIP
2.45
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Cell Reports Medicine

Cell Reports Medicine Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • DOAJ DOAJ
  • SJR SJR
Overview
Publisher ELSEVIER
Language English
Frequency Monthly
Article Processing ChargesUSD 5460
Publication Time17
Editorial Review ProcessAnonymous peer review
General Details
LanguageEnglish
FrequencyMonthly
Publication Start Year2020
Publisher URLVisit website
Website URLVisit website
Publication Details
PlagiarismVisit website
Publication Time 17
Waiver PolicyVisit website
Editorial Review Detail
Editorial TeamVisit website
Review ProcessAnonymous peer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Copyright DetailsVisit website
License typeCC BY, CC BY-NC-ND
OA statementVisit website
View less

Planning to publish in Cell Reports Medicine ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Cell Reports Medicine

High-dose furmonertinib as first-line treatment for untreated EGFR-mutated advanced NSCLC with central nervous system metastases: A phase 2 trial.
  • 30 Jun 2026
  • Cell reports. Medicine
A radiopharmaceutical enhances CAR T cells against radio-sensitive and radio-resistant neuroblastoma by tumor sensitization and TME remodeling.
  • 23 Jun 2026
  • Cell reports. Medicine
Commensal Cutibacterium acnes-derived indolelactic acid safeguards skin barrier function through the aryl hydrocarbon receptor.
  • 23 Jun 2026
  • Cell reports. Medicine
Spatial architecture contributes to failure of bulk biomarker-guided neoadjuvant immunotherapy selection in bladder cancer: The DUTRENEO study.
  • 23 Jun 2026
  • Cell reports. Medicine
Safety and efficacy of GZR18, a long-acting GLP-1 analog, in Chinese patients with type 2 diabetes: A randomized, double-blind, phase 1b/2a trial.
  • 19 Jun 2026
  • Cell reports. Medicine
Elevated cfDNA after exercise is derived primarily from mature polymorphonuclear neutrophils, with a minor contribution of cardiomyocytes.
  • 19 Jun 2026
  • Cell reports. Medicine
High-dose furmonertinib as first-line treatment for untreated EGFR-mutated advanced NSCLC with central nervous system metastases: A phase 2 trial.
  • 30 Jun 2026
  • Cell reports. Medicine
A radiopharmaceutical enhances CAR T cells against radio-sensitive and radio-resistant neuroblastoma by tumor sensitization and TME remodeling.
  • 23 Jun 2026
  • Cell reports. Medicine
Commensal Cutibacterium acnes-derived indolelactic acid safeguards skin barrier function through the aryl hydrocarbon receptor.
  • 23 Jun 2026
  • Cell reports. Medicine
Spatial architecture contributes to failure of bulk biomarker-guided neoadjuvant immunotherapy selection in bladder cancer: The DUTRENEO study.
  • 23 Jun 2026
  • Cell reports. Medicine
Safety and efficacy of GZR18, a long-acting GLP-1 analog, in Chinese patients with type 2 diabetes: A randomized, double-blind, phase 1b/2a trial.
  • 19 Jun 2026
  • Cell reports. Medicine
Elevated cfDNA after exercise is derived primarily from mature polymorphonuclear neutrophils, with a minor contribution of cardiomyocytes.
  • 19 Jun 2026
  • Cell reports. Medicine

FAQs on Cell Reports Medicine